Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin in Cystic Fibrosis-Related Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years of age or older~* Cystic fibrosis-related diabetes with or without fasting hyperglycemia either untreated or using only pre-prandial repaglinide or pre-prandial bolus insulin therapy~Exclusion Criteria:~* Age under 19 years~* Use of basal insulin therapy~* Creatinine Clearance \< 50 mL/min~* Active cystic fibrosis exacerbation~* Pregnancy~* Women of child-bearing age not using effective contraception~* Current or prior use of DPPIV inhibitor

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).